Nucor earnings beat by $0.08, revenue fell short of estimates
Zai Lab Ltd (NASDAQ:ZLAB), a pharmaceutical company with a market capitalization of $3.98 billion and impressive 129% return over the past year, saw its Chairperson and CEO Du Ying recently sell 5,808 American Depositary Shares (ADS) valued at approximately $208,472. The transaction, which occurred on April 2, 2025, was part of a series of activities detailed in a recent SEC Form 4 filing.
The shares were sold at an average price of $35.894 per share. This sale was made to cover taxes upon the vesting of Restricted Share Units (RSUs), according to the filing.
In addition to the sale, Du Ying acquired a total of 14,200 ADSs through the vesting of RSUs on April 1, 2025. Each RSU represents a contingent right to receive one ADS, with these units vesting annually over five years.
Following these transactions, Du Ying holds a total of 476,046 ADSs in Zai Lab, maintaining a significant stake in the Shanghai-based pharmaceutical company. According to InvestingPro analysis, the company shows promising revenue growth of nearly 50% but remains in investment phase. Get access to 10+ additional ProTips and comprehensive analysis with an InvestingPro subscription.
In other recent news, Zai Lab has been the focus of several analyst reports highlighting its potential and challenges. Cantor Fitzgerald maintained an Overweight rating, emphasizing the growth prospects of Bemarituzumab, which is undergoing Phase 3 trials. The firm projects potential peak sales nearing $1 billion, though investor expectations are mixed. Scotiabank (TSX:BNS) initiated coverage with a Sector Outperform rating and a price target of $55, citing Zai Lab’s potential to become a global pharmaceutical leader. The analyst expects the company to achieve cash flow positivity by the fourth quarter of 2025, a significant milestone.
Meanwhile, BofA Securities downgraded Zai Lab from Buy to Neutral, though it raised the price target to $36.10. This adjustment reflects a tempered outlook due to the soft performance of Zejula/Optune, despite promising developments in the pipeline. Analysts noted the sales ramp-up of VYVGART and potential advancements with Optune for pancreatic cancer. The firm also adjusted its financial models, reflecting an updated revenue forecast starting in 2027. Investors are closely monitoring these developments as Zai Lab continues to navigate its strategic and financial landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.